MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1371/journal.pone.0332645

Медицинская библиотека · PloS one · 2025

Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in North Carolina from December 2020 - February 2022.

Miller Elyse M, Boyce Ross M, Kipp Aaron M, Newby L Kristin, Woods Christopher W, Cassidy Caitlin A, Gunderson Annika K, Lea C Suzanne, Neighbors Coralei E, Shook-Sa Bonnie E, Sloane Richard, Starling Anne P, Wambui David, Wixted Douglas, Fleischauer Aaron, Aiello Allison E

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Surveillance estimates of SARS-CoV-2 infections over time have relied on mandatory clinician and laboratory reporting. These estimates increasingly underestimated true viral incidence due to asymptomatic infections, variable access to testing, and self-administered diagnostics. To overcome these limitations, the North Carolina Department of Health and Human Services partnered with academic researchers to conduct three concurrent population-based longitudinal cohort studies in three distinct North Carolina counties to offer more accurate estimates of the incidence, prevalence, and vaccination rates for SARS-CoV-2.

METHODS

We enrolled and followed adult residents of three North Carolina counties from August 2020-February 2022. Demographic and health information was collected in biweekly surveys. Nasal swabs were collected biweekly and tested for SARS-CoV-2 using PCR testing. Blood samples were collected monthly and tested for antibodies to the SARS-CoV-2 nucleocapsid and spike proteins. We calculated monthly seroprevalence, sero-incidence, PCR test positivity, and vaccination uptake.

RESULTS

We enrolled 646 participants. Routine blood samples and nasal swab samples were contributed by 639 and 642 participants, respectively. By February 2022, 98% (95% CI: 97.4-98.2) had antibodies to the SARS-CoV-2 spike protein, and 13% (95% CI: 12.4-14.2) had antibodies to the nucleocapsid protein, indicating viral exposure. PCR testing detected infection among 14% (95% CI: 13.1-15.0) of participants, but cumulative PCR test positivity was only 1.3% (95% CI: 1.2-1.4). Over half of PCR-detected infections were asymptomatic. By February 2022, 97% of participants had completed the primary vaccine series, and 52% had received a booster dose.

CONCLUSIONS

Nearly all participants had anti-SARS-CoV-2 antibodies by the end of follow-up, primarily through vaccination. The incidence of PCR-detected infections was similar to antibody testing, but PCR test positivity substantially underestimated incident infections. These findings emphasize the importance of prospective infection monitoring via antibody testing in a comprehensive approach to tracking viral infections in the community setting.

Для цитирования: Miller Elyse M, Boyce Ross M, Kipp Aaron M, Newby L Kristin, Woods Christopher W, Cassidy Caitlin A, Gunderson Annika K, Lea C Suzanne, Neighbors Coralei E, Shook-Sa Bonnie E, Sloane Richard, Starling Anne P, Wambui David, Wixted Douglas, Fleischauer Aaron, Aiello Allison E. Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in North Carolina from December 2020 - February 2022.. PloS one. 2025. DOI: 10.1371/journal.pone.0332645.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.